Investor Presentaiton

Lead BION-206 agent is in pre-clinical development A lead clone has been isolated and characterized for: Specific binding to CD28 proteolytic site Clean safety profile - no agonistic or antagonistic activity Prevents receptor shedding in various immune assays OD (450nm) BIOND BIOLOGICS 5. 4 3 0.01 0.1 1 BION-206 (μg/ml) CD28 Targeted shedding site T cell In-vitro blocking CD28 cleavage by MMP-2 1.2 n-cells CD28-shedding blocking activity 5000 1 0.8 0.6 0.4 0.2 0 10 Peptide MMP-2 0.024 0.12 0.6 MMP-2 + BION 206 (μM) 4000- 3000 2000 1000 Biond Biologics Corporate Presentation | May 2021 | Non-confidential H No Stim. SEB SEB+ TMI-1 0,024 0.12 0.6 3 SEB + BION 206 (μM) 涯 20 20

View entire presentation